Overview

The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever

Status:
COMPLETED

Trial end date:
2025-05-29

Target enrollment:

Participant gender:

Summary

This study investigates the comparative efficacy of standard treatment plus Ribavirin versus standard treatment alone in preventing clinically significant hemorrhage among patients diagnosed with dengue fever. It is a double-blind, randomized control trial aimed at determining whether the addition of Ribavirin improves clinical outcomes, particularly reducing bleeding events.

Phase:

PHASE3

Details

Lead Sponsor:

Khyber Medical University Peshawar

Treatments:

Ribavirin